Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
=======================================================================================================================================

* Patrick Schöffski
* Daniel S W Tan
* Miguel Martín
* María Ochoa-de-Olza
* John Sarantopoulos
* Richard D Carvajal
* Chrisann Kyi
* Taito Esaki
* Amy Prawira
* Wallace Akerley
* Filippo De Braud
* Rina Hui
* Tian Zhang
* Ross A Soo
* Michela Maur
* Andrew Weickhardt
* Jürgen Krauss
* Barbara Deschler-Baier
* Allen Lau
* Tanay S Samant
* Tyler Longmire
* Niladri Roy Chowdhury
* Catherine A Sabatos-Peyton
* Nidhi Patel
* Radha Ramesh
* Tiancen Hu
* Ana Carion
* Daniel Gusenleitner
* Padmaja Yerramilli-Rao
* Vasileios Askoxylakis
* Eunice L Kwak
* David S Hong